-

Dexcom Canada Achieves Great Place to Work® Certification

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work® in Canada for 2022-23. Awarded by Great Place to Work Institute® Canada, the global authority on high-trust, high-performance workplace cultures, this prestigious certification is based on direct feedback from employees and demonstrates Dexcom’s commitment to fostering a workplace culture rooted in transparency, respect, fairness, pride and camaraderie. This year, 92 per cent of employees said they feel proud to tell others they work at Dexcom Canada.

“We are incredibly honoured to be recognized as a Great Place to Work in Canada,” says Laura Endres, Senior Vice President, North America. “This achievement would not be possible without our amazing employees who exemplify Dexcom’s values of being dependable, listening, serving with integrity and thinking big, every day.”

Nancy Fonseca, Senior Vice President of Great Place to Work® Canada, says that a great workplace is about the level of trust that employees experience in their leaders, the level of pride they have in their jobs, and the extent to which they enjoy their colleagues. "Our data shows that great workplaces benefit from stronger financial performance, reduced turnover, and better customer satisfaction than their peers. What's more, work environments with trust at the foundation are ripe for innovation, agility, resilience and efficiency," Fonseca said.

Dexcom Canada is dedicated to raising the bar on the employee experience and continuing to cultivate a workplace culture where employees are celebrated, empowered with professional growth and career advancement opportunities, and carry meaningful purpose working to improve lives for people living with diabetes. “Our team is truly exceptional, with each person playing an integral part in helping build the amazing culture we have. We will continue to seek feedback from our employees, learn and improve to ensure that Dexcom Canada remains an engaging place to work for many years to come,” says Iris Nikolic, HR Business Partner.

Dexcom Canada continues to expand its presence across Canada and bring life-changing diabetes management technology to more Canadians. Visit Dexcom’s Careers page to learn more about available opportunities to join our team.

About Dexcom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

About Great Place to Work®
Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, Great Place to Work recognizes Canada’s Best Workplaces in a series of national lists including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Great Place to Work provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. Visit us at www.greatplacetowork.ca or find us on Twitter at @GPTW_Canada.

Contacts

Media Contact
Alena Atkinson, 705.206.9991
Veritas Communications
atkinson@veritasinc.com

Dexcom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
Alena Atkinson, 705.206.9991
Veritas Communications
atkinson@veritasinc.com

More News From Dexcom, Inc.

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom